VivoSeq
Other

Fever

22

Pipeline Programs↗

1

Active Trials↗

14

Companies Involved↗

Fever is an emerging landscape with 22 programs across 14 companies. The most active players are Roche, Novartis, Eastern Cooperative Oncology Group. 11 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

6/100

Mech. Concentration

21/100

Completion Rate

89/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3Sanofi logo

Sanofi

2 programs

Phase 3K

Kenvue Brands

2 programs

ApprovedBayer logo

Bayer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

76%

Small molecule

16 of 21 classified programs — the dominant modality here.

24%ALL OTHERSMonoclonal antibody314%Protein / enzyme15%Vaccine15%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 92% of 24 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed8 · 80%
Suspended1 · 10%
Recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Optimisation du Parcours de Soins Des Enfants fébriles Par l'Utilisation de la CRP Capillaire en Soins Primaires : Protocole d'un Essai Multicentrique randomisé
Recruiting·CCentre Hospitalier Universitaire de Nīmes·Preclinical·NCT06910631·420 enrolled
Drug Utilization Study for Pirinase Hayfever Relief
Completed·GSK logoGSK·N/A·NCT02856282·46 enrolled
A Trial of the ALK Grass Tablet in Subjects With Hayfever
Completed·AALK-Abelló A/S·Phase 3·NCT00227279·634 enrolled
A Trial of Grazax in Subjects With Hayfever
Completed·AALK-Abelló A/S·Phase 3·NCT00421655·329 enrolled
Empiric Therapy of Patients With Persistent Fever and Agranulocytosis Using Caspofungin
Completed·CCttq·Phase 2·NCT03857399·32 enrolled
A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever
Completed·TTTY Biopharm·N/A·NCT03511820·54 enrolled
Control of Fever in Septic Patients
Completed·UUniversity Hospital Ostrava·N/A·NCT04227652·140 enrolled
Tolerability of Grazax in Patients With Hayfever in Real Life Settings
Completed·AALK-Abelló A/S·Phase 4·NCT01433510·628 enrolled
A Phase I, Randomised, Open Label, Single Center, Single Oral Dose, Three Treatment, Three Period, Three Sequence, Change-over Bioequivalence Study of Paracetamol Orodispersible Tablet 500 mg (Haleon) to Assess Bioequivalence With Alvedon 500 mg Film-Coated Tablet (Haleon, Sweden) and Panadol 500 mg Film-Coated Tablet (Haleon, Australia) in Healthy Adult Subjects Under Fasting Conditions
Completed·HHALEON·Phase 1·NCT06855576·54 enrolled
Rituximab in Patients With Acute Rheumatic Fever
Suspended·AAfrican Academy of Methodology and Statistics·Phase 2·NCT05682196·234 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)